Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
Tesla Raises Cybertruck Prices by $5,000 in US 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Nvidia Options Price in $280 Billion Earnings Swing 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Add as a preferred source on Google
Press release - No 11 / 2018
Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018
Copenhagen, 2 May, 2018 - Mats Blom, Executive Vice President and Chief Financial Officer (CFO) of Zealand Pharma, will be presenting at the Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018.
For further information, please contact:
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.
Attachment
